Ronan Craig
Biography
Ronan is a Corporate associate in London. He advises, as part of a team, a number of leading private equity funds and major corporates on a wide range of domestic and cross-border acquisitions, disposals and restructurings, as well as portfolio companies on general corporate matters.
Representative experience as part of a team, including prior to joining Weil, includes advising:
- PX3 Partners, and its portfolio company Cleanova, on the acquisition of the Micronics Engineered Filtration Group, creating a $1.3bn combined business
- Advent on the €3.9bn sale of Aareon to TPG and CDPQ and Advent’s reinvestment into Aareon alongside them
- Advent on the recommended cash offer for UK-listed Spectris plc
- Bain Capital on the £1.295bn sale of esure to Ageas
- Apse Capital on a €350m multi-asset continuation fund transaction
- Lead Seller group on the $2bn sale of KCA Deutag to Helmerich & Payne
- M&G Catalyst on its investments in Nearfield Instruments and Submer
- Charterhouse Capital Partners on its acquisition of Two Circles from Bruin Sports Capital
- Charterhouse Capital Partners on its sale of SLR Consulting to Ares Management
- Compass Partners on its sale of Infinitas Learning to NPM Capital
- Correlation Risk Partners on its sale of Animal Friends to JAB Holding Company
- PA Consulting on its private equity-style partnership with Jacobs Engineering Group
- Vitruvian Partners on its sale of Phlexglobal to Cencora PharmaLex
Prior to joining Weil, Ronan was an associate at a US-headquartered international firm in London.
He has spent time on secondment to Vitruvian Partners.
Firm News & Announcements
Firm News & Announcements
- Weil Advises Advent on the £3.8B Recommended Cash Offer for Spectris Deal Brief — June 24, 2025
- Weil Advises Bain Capital and esure on the Sale of esure to Ageas Deal Brief — April 15, 2025
- Weil Advises PX3 Partners in Cleanova’s Definitive Agreement to Acquire Micronics Deal Brief — March 05, 2025
- Weil Advises Apse Capital Limited on the Closing of a €350 Million Continuation Fund Firm Announcement — November 27, 2024